Your browser doesn't support javascript.
loading
Benefits, Harms, and Cost-Effectiveness of Potential Age Extensions to the National Bowel Cancer Screening Program in Australia.
Lew, Jie-Bin; St John, D James B; Macrae, Finlay A; Emery, Jon D; Ee, Hooi C; Jenkins, Mark A; He, Emily; Grogan, Paul; Caruana, Michael; Greuter, Marjolein J E; Coupé, Veerle M H; Canfell, Karen.
Afiliação
  • Lew JB; Cancer Research Division, Cancer Council New South Wales, Sydney, Australia. jiebin.lew@nswcc.org.au.
  • St John DJB; Prince of Wales Clinical School, UNSW, Sydney, Australia.
  • Macrae FA; Prevention Division, Cancer Council Victoria, Melbourne, Victoria, Australia.
  • Emery JD; Department of Medicine, The Royal Melbourne Hospital, The University of Melbourne, Victoria, Australia.
  • Ee HC; Department of Medicine, The Royal Melbourne Hospital, The University of Melbourne, Victoria, Australia.
  • Jenkins MA; Department of Colorectal Medicine and Genetics, and Department of Medicine, The Royal Melbourne Hospital and University of Melbourne, Victoria, Australia.
  • He E; Department of General Practice and Centre for Cancer Research, University of Melbourne, Victorian Comprehensive Cancer Centre, Melbourne, Australia.
  • Grogan P; Primary Care Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kindgom.
  • Caruana M; Department of Gastroenterology, Sir Charles Gairdner Hospital, Western Australia, Australia.
  • Greuter MJE; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Victoria, Australia.
  • Coupé VMH; Cancer Research Division, Cancer Council New South Wales, Sydney, Australia.
  • Canfell K; Prince of Wales Clinical School, UNSW, Sydney, Australia.
Cancer Epidemiol Biomarkers Prev ; 27(12): 1450-1461, 2018 12.
Article em En | MEDLINE | ID: mdl-30190276
BACKGROUND: The Australian National Bowel Cancer Screening Program (NBCSP) is rolling out 2-yearly immunochemical fecal occult blood test screening in people aged 50 to 74 years. This study aimed to evaluate the benefits, harms, and cost-effectiveness of extending the NBCSP to younger and/or older ages. METHODS: A comprehensive validated microsimulation model, Policy1-Bowel, was used to simulate the fully rolled-out NBCSP and alternative strategies assuming screening starts at 40 or 45 years and/or ceases at 79 or 84 years given three scenarios: (i) perfect adherence (100%), (ii) high adherence (60%), and (ii) low adherence (40%, as currently achieved). RESULTS: The current NBCSP will reduce colorectal cancer incidence (mortality) by 23% to 51% (36% to 74%) compared with no screening (range reflects participation); extending screening to younger or older ages would result in additional reductions of 2 to 6 (2 to 9) or 1 to 3 (3 to 7) percentage points, respectively. With an indicative willingness-to-pay threshold of A$50,000/life-year saved (LYS), only screening from 50 to 74 years [incremental cost-effective ratio (ICER): A$2,984-5,981/LYS) or from 45 to 74 years (ICER: A$17,053-29,512/LYS) remained cost-effective in all participation scenarios. The number-needed-to-colonoscope to prevent a death over the lifetime of a cohort in the current NBCSP is 35 to 49. Starting screening at 45 years would increase colonoscopy demand for program-related colonoscopies by 3% to 14% and be associated with 55 to 170 additional colonoscopies per additional death prevented. CONCLUSIONS: Starting screening at 45 years could be cost-effective, but it would increase colonoscopy demand and would be associated with a less favorable incremental benefits-to-harms trade-off than screening from 50 to 74 years. IMPACT: The study underpins recently updated Australian colorectal cancer management guidelines that recommend that the NBCSP continues to offer bowel screening from 50 to 74 years.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Análise Custo-Benefício / Neoplasias do Colo Tipo de estudo: Diagnostic_studies / Evaluation_studies / Health_economic_evaluation / Prognostic_studies / Screening_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Oceania Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Análise Custo-Benefício / Neoplasias do Colo Tipo de estudo: Diagnostic_studies / Evaluation_studies / Health_economic_evaluation / Prognostic_studies / Screening_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Oceania Idioma: En Ano de publicação: 2018 Tipo de documento: Article